The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant from the National Heart, Lung and Blood Institute of the National Institutes of Health Entitled “Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis”
Doylestown, PA. September 17, 2018 – FCCDC is pleased to announce that it has been awarded a Phase I SBIR grant from the National Heart, Lung and Blood Institute of the National Institutes of Health entitled “Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis” (1R43HL140712-01A1).